[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100413542":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":19,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":19,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":19,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"General Hospital of Shenyang Military Region","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Intra-arterial administration of 3-n-butylphthalide","EXPERIMENTAL","Intra-arterial administration of 3-n-butylphthalide for 24 hours via microcatheter at 17.36 ug\u002Fmin.",[13],"Drug: Intra-arterial administration of neuroprotective agents",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","Intra-arterial administration of neuroprotective agents",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Hui-Sheng T Chen, Ph.D.","CONTACT","+8613352452086","chszh@aliyun.com",[27],{"facility":28,"status":29,"city":30,"state":19,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Department of Neurology, General Hospital of Northern Theater Command","RECRUITING","Shenyang","110016","China","CN",{"type":35,"coordinates":36},"Point",[37,38],123.43278,41.79222,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":19,"email":25},"Hui-Sheng Chen, Ph.D.","+86 13352452086",{"type":45,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"SPONSOR_INVESTIGATOR","Hui-Sheng Chen","Director","100413542","intra-arterial-neuroprotective-strategy-for-ischemic-stroke-patients-with-no-reperfusion-therapy-insist-nrt-100413542",false,"NCT04664946","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT): One Single Center, Safety and Feasibility Study","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Major neurologic deficits: 6≤NIHSS≤20;\n3. Missing recanalization therapy (IVT or EVT) or progressive stroke, which was defined as symptoms worsen in 48 hours (an increase in NIHSS more than 4);\n4. Premorbid mRS 0 or 1;\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. Modified Rankin Score \\>2 caused by a history of prior stroke;\n2. Patients who underwent intravenous thrombolysis or Endovascular treatment;\n3. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ \\\u003C80000\u002Fmm3;\n4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n5. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);\n6. Unsuitable for this clinical studies assessed by researcher.","ALL","18 Years",{"count":58,"type":59},30,"ESTIMATED","INTERVENTIONAL",[62],"NA","To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who missed recanalization operation.",[65,66],"Ischemic Stroke","Neuroprotection","2025-08-20",{"date":69,"type":70},"2025-08-21","ACTUAL",{"date":72,"type":70},"2020-12-01",{"date":74,"type":59},"2026-05-01",{"name":46,"class":6},1]